Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2005

View Archived Issues

N-Acetylcysteine shown to decrease craving in hospitalized cocaine addicts

NFPS potentiates the effect of risperidone on glutamatergic transmission

ABT-510 effective against preclinical and clinical hematological malignancies

Ezetimibe improves lipid parameters in HIV-infected subjects with dyslipidemia

A-60444: synergistic combinations and phase I data

Open study finds escitalopram improves depression in perimenopausal women

Preliminary data from phase I/II study of HuMax-CD20 in CLL

Idiotype vaccination may enhance rituximab therapy in non-Hodgkin's lymphoma

New antibiotic for resistant Gram-positive bacteria

Pan-Bcl inhibitor shows preclinical and early clinical activity in patients with CLL

Promising results for GTI-2040 in younger patients with acute myeloid leukemia

Treatment under way in phase II study of HER-2 Protein AutoVac with QS-21

Merck & Co. restructures R&D, reviews pipeline progress

CollaGenex to acquire SansRosa Pharmaceutical Development

Apoxis acquires rights to anticancer compound from Astellas

European phase III study for SNT-MC17 in Friedreich's ataxia

Crucell opens enrollment in phase I study of West Nile virus vaccine

Roche completes four pivotal studies for CERA in renal anemia

Novartis terminates development of NKS-104

Merck begins phase I trial for S. aureus vaccine

Inhibition of PKA and calcineurin protects against seizures

MedImmune completes enrollment in Numax studies

First study describing androstenol's anticonvulsant properties

Cyclacel and Xcyte Therapies to combine companies

CytRx and UMMS sign agreement for obesity and type diabetes targets

Second clinical study for CTCE-0214

Phase IIa trial of PW-4142 completes enrollment

Corgentech and AlgoRx complete merger

Significant bone activity of Acapodene confirmed in ADT patients

Recent patents cover novel treatment options for cancer

Genentech submits sBLA for Avastin in relapsed metastatic colorectal cancer

Norepinephrine reuptake inhibitors for ADHD emerge from Pfizer R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...